Lead candidate ARD-101 demonstrated clinical activity and was generally well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome (PWS), with meaningful reductions in hyperphagia (up to a 16 ...
Long-time Valve VR programmer Joe Ludwig, working in his own capacity, is building an open-source platform to bring AR-like utilities into virtual reality. The project, called Aardvark, is something ...
Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia ...
Aardvark to host Investor Webinar with members of the management team, leading key opinion leaders and patient advocates on November 5, 2025 SAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Aardvark ...
SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics ...
SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (“Aardvark”) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback